GlassScriptPhysician profile
Akash I Patel
NPI 1841552635
$2,317.64
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $317 · 2021: $526 · 2022: $981.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $842.70 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $311.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $248.33 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $133.74 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $120.25 | 2021-2022 | |
| Advanced Respiratory, INC | $106.15 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.10 | 2020-2021 | |
| Amgen INC. | $40.02 | 2022 | |
| Gilead Sciences, INC. | $35.25 | 2021-2022 | |
| Ucb, INC. | $34.38 | 2022 | |
| Boston Scientific Corporation | $33.40 | 2020 | |
| Pfizer INC. | $32.18 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.73 | 2022 | |
| W. L. Gore & Associates, INC. | $19.07 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $16.20 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akash Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.